Bone Mineral Density News and Research

RSS

$IOF report predicts major increase in osteoporosis fractures in the Middle East and Africa$

IOF report predicts major increase in osteoporosis fractures in the Middle East and Africa

A new audit report issued today by the International Osteoporosis Foundation (IOF) shows that osteoporosis is a serious and growing problem throughout the Middle East and parts of Africa.

22 Oct 2011

Six young investigators receive IOF's Young Investigator Award for bone research

Six young investigators from the Middle East have been awarded prestigious grants in recognition of their top ranked research abstracts presented at the IOF Regionals - 1st Middle-East & Africa Osteoporosis Meeting.

22 Oct 2011

NCKU research team discovers potential target to treat osteoporosis

A National Cheng Kung University (NCKU) research team has discovered that a protein called interleukin (IL)-20 is a key to treating osteoporosis, a disease that lowers a person's bone density.

7 Oct 2011

Top-line data from Santarus' budesonide MMX extended use study on ulcerative colitis

Santarus, Inc., a specialty biopharmaceutical company, today announced that analysis of top-line safety data from a double blind, multicenter 12-month extended use study in patients treated daily with either the investigational drug budesonide MMX 6 mg or placebo will be provided as support for the company's planned submission of a New Drug Application (NDA) for budesonide MMX 9 mg to the U.S. Food and Drug Administration (FDA) for the induction of remission of mild or moderate active ulcerative colitis.

20 Sep 2011

Amgen's Prolia receives FDA approval for new indications to treat cancer patients

Amgen today announced that the U.S. Food and Drug Administration (FDA) approved two new indications for Prolia® (denosumab) as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer and as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for non-metastatic prostate cancer.

19 Sep 2011

FDA advisory panel suggests warning for bisphosphonates but does not specify wording

Two independent advisory panels to the Food and Drug Administration (FDA) on Friday recommended increasing the cautionary language on the product labels of bone-building drugs taken by more than five million women in the United States. They did not however mention the exact words of the safety warnings and did not recommend limiting use of the drugs to a proposed five years. About 11 percent of women 55 and older take the drugs to prevent bone fractures.

12 Sep 2011

IOF presents eight young investigator awards to researchers across the world

Eight IOF Young Investigator Awards were presented by the International Osteoporosis Foundation (IOF) to young researchers from Australia, China, India and Japan, in recognition of their outstanding work. The awards, valued at 1,000 USD each, were awarded to the highest scored abstracts by researchers under the age of 40.

7 Sep 2011

Amgen to present data from several Prolia studies at ASBMR 2011 meeting

Amgen today announced that it will present data from several Prolia (denosumab) studies, including eight year efficacy and safety data from a Phase 2 extension study in women with postmenopausal osteoporosis with low bone mineral density (BMD), at the 2011 American Society for Bone and Mineral Research (ASBMR) Annual Meeting in San Diego, Calif. from Sept. 16-20, 2011.

19 Aug 2011

$Dried plums can protect postmenopausal women against fractures, osteoporosis$

Dried plums can protect postmenopausal women against fractures, osteoporosis

When it comes to improving bone health in postmenopausal women — and people of all ages, actually — a Florida State University researcher has found a simple, proactive solution to help prevent fractures and osteoporosis: eating dried plums.

19 Aug 2011

FDA approves Gilead's Complera for treatment of HIV-1 infection

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Complera, a complete single-tablet regimen for the treatment of HIV-1 infection in treatment-naïve adults.

11 Aug 2011

Current Medical Research & Opinion publishes new data on EVISTA for postmenopausal osteoporosis

Eli Lilly and Company today announced that data on EVISTA® (raloxifene HCl tablets) therapy for more than three years was published online in Current Medical Research & Opinion.

10 Aug 2011

Soy useless for menopause

In their two year study they found that there were no differences in changes in bone density or menopausal symptoms between women taking soy and those taking a placebo, although women taking isoflavones did have more hot flashes, Dr. Silvina Levis of the University of Miami and colleagues reported in the August 8/22 issue of Archives of Internal Medicine.

8 Aug 2011

Amgen reports 8% increase in second quarter total product sales to $3,893 million

Amgen reported total revenue increased 4 percent during the second quarter of 2011 to $3,959 million versus $3,804 million in the second quarter of 2010. Total product sales increased 8 percent in the second quarter of 2011 to $3,893 million versus $3,613 million in the second quarter of 2010. The increase in total revenue in the second quarter of 2011 included a decline in other revenue due to certain milestone payments earned in the second quarter of 2010.

29 Jul 2011

Strength exercises boost bone density in postmenopausal women with osteoporosis

Women with osteoporosis - a skeletal disease that erodes bone density, weakens bone strength and increases the risk of fractures - might think taking it easy is the best way to prevent bone breaks.

13 Jul 2011

$More patients tested, treated when fracture clinics have someone dedicated to screening$

More patients tested, treated when fracture clinics have someone dedicated to screening

More patients are tested and treated for osteoporosis when fracture clinics have someone dedicated to screening for the bone disease, a new study has found.

12 Jul 2011

Experiment to protect astronauts from bone loss during micro-gravity exposure

Researchers in the University of North Carolina at Chapel Hill/North Carolina State University Joint Department of Biomedical Engineering will be at the Kennedy Space Center for the last space shuttle launch of the NASA program as Atlantis departs for its final mission into Earth's orbit.

6 Jul 2011

Resveratrol may prevent negative effects of spaceflight and sedentary lifestyles

As strange as it sounds, a new research study published in the FASEB Journal (http://www.fasebj.org), suggests that the "healthy" ingredient in red wine, resveratrol, may prevent the negative effects that spaceflight and sedentary lifestyles have on people.

1 Jul 2011

Vitamin D supplements safe for healthy pregnant women

Use of vitamin D supplements during pregnancy has long been a matter of concern but now researchers writing in the Journal of Bone and Mineral Research report that even a high supplementation amount in healthy pregnant women was safe and effective in raising circulating vitamin D to a level thought by some to be optimal. The study also found no adverse effects of vitamin D supplementation, even at the highest amount, in women or their newborns.

27 Jun 2011

GTx commences Capesaris Phase IIb trial in advanced prostate cancer

GTx, Inc., announced today that it initiated a Phase IIb clinical trial evaluating Capesaris, a selective estrogen receptor alpha agonist, compared to Lupron Depot for first line treatment of advanced prostate cancer.

20 Jun 2011

$New report: Only minority of high risk patients receive treatment to prevent fractures$

New report: Only minority of high risk patients receive treatment to prevent fractures

In Europe, a serious treatment gap is leaving millions of people at high risk of fragility fractures. The findings were revealed in 'Osteoporosis: Burden, health care provision and opportunities in the EU', a landmark report prepared by the International Osteoporosis Foundation (IOF) in collaboration with the European Federation of Pharmaceutical Industry Associations.

17 Jun 2011